Changes in VLDL triglyceride and VLDL apo B production were determined semiquantitatively in healthy young men by examining the effect of altering plasma insulin and/or FFA levels on the change in the slopes of the specific activity of VLDL [3H]triglyceride glycerol or the "'I-VLDL apo B versus time curves.
Introduction
Chronic hyperinsulinemia has been shown to stimulate triglyceride turnover in animal models (1) and insulin itself has been postulated to play a facilitatory role in the overproduction of hepatic (VLDL) particles in certain insulin-resistant states (2) . Short-term addition of insulin to culture media, on the other hand, has been shown to inhibit VLDL triglyceride and apo B production in vitro in cultured rat and human hepatocytes (3) (4) (5) (6) (7) (8) (9) (10) and HepG2 cells (11) (12) (13) (14) (15) . By contrast, studies using perfused rat livers have generally shown an acute stimulatory effect of insulin (16) (17) (18) (19) (20) . We have previously provided some of the first in vivo evidence that acute hyperinsulinemia suppresses VLDL apo B and triglyceride production in humans (21, 22) .
Free fatty acids, when added to the hepatocyte or Hep G2 cell culture medium, have been shown to stimulate production of VLDL triglyceride and apo B in vitro (11-13, 15, [23] [24] [25] [26] [27] [28] and to attenuate the acute inhibitory effect of insulin (11, 13, 15) . Plasma FFA levels are exquisitely sensitive to acute changes in the ambient insulin concentration in healthy insulinsensitive individuals (29) , hence insulin, in vivo, may also indirectly regulate VLDL production by reducing plasma levels of FFA as a consequence of its inhibitory effect on adipose tissue hormone sensitive lipase (30) .
In our previous studies examining the acute in vivo effect of insulin on VLDL production we noted a dramatic reduction in plasma FFA concentration within 1 h of the onset of acute hyperinsulinemia (21, 22) . In those studies it was not possible to determine whether the acute inhibitory effect of insulin on VLDL production was entirely mediated by the suppression of substrate (FFA) availability for VLDL synthesis. The present study examines the role played by FFA in mediating insulin's effect on VLDL production. Currently described mathematical modeling techniques designed to quantify absolute VLDL production rates are limited to steady-state conditions and require prolonged sampling periods. Therefore we have used a semiquantitative radiolabeled VLDL tracer technique as previously described to estimate the relative changes in VLDL triglyceride and VLDL apo B production rates compared to baseline (21) . This Using this technique, in this paper we have tested the hypothesis that insulin has an acute suppressive effect on VLDL production independent of its effects on FFA. Eight healthy young male volunteers were studied on two occasions each. On one occasion, plasma FFA levels were allowed to fall during acute hyperinsulinemia. On the subsequent occasion plasma FFA levels were acutely raised approximately twofold during hyperinsulinemia by infusing heparin and Intralipid (Baxter Corp.). This provided an opportunity to compare the effects of two different levels of FFA while peripheral insulin levels were matched. Eight additional subjects were studied at basal insulin levels while infusing heparin and Intralipid to raise plasma FFA levels twofold. The latter study permitted a comparison of the effects of two different levels of peripheral insulinemia while matching plasma FFA concentrations.
Methods
Subjects 16 healthy male volunteers (age = 26.1 + 1.4 yr, body mass index = 23.6+0.5 kg/mr2) participated in the study. Subjects with hyperlipidemia or any systemic illness were excluded from the study. No subject was taking any medication at the time of the study, and subjects were asked to refrain from drinking alcohol for 1 wk before the study. All had stable body weight for the month before the study. Subjects were instructed to consume their regular diet until 1800 h of the evening before the study, and then to fast. Informed written consent was obtained from all participants in accordance with the guidelines of the University of Toronto Human Subjects Review Committee. All studies were conducted in The Toronto Hospital Clinical Investigation Unit.
Experimental protocol
Each of eight subjects was studied on two occasions, 8 wk apart. Each underwent a euglycemic hyperinsulinemic clamp on one occasion (insulin infusion study) and the same clamp plus heparin and Intralipid on another (insulin-heparin-Intralipid study). The order of these studies was randomly assigned. In an attempt to limit the exposure to radioactive iodine, each subject was studied on a maximum of two occasions each. Therefore an additional eight subjects participated in the third study, receiving heparin and Intralipid without the clamp (heparin-intralipid study).
5-7 d before the study, -450 ml of blood was drawn, the plasma separated, and the red cells returned to the subject. 250 ml plasma was separated from the blood and VLDL (d < 1.006 g/ml, Svedberg flotation constant [Sf] 20-400) isolated from the plasma under sterile conditions by spinning in a 50.2 Ti rotor for 16 h at 32,000 rpm (108,000 g) and 10C. The VLDL was washed once. Apo B was then iodinated with '1'I using sterile techniques by modification of the method described by
McFarlane (31) . The '31I-VLDL apoB was checked for sterility and freedom from pyrogens.
The volunteers consumed their usual diet until 1800 h of the evening before the study. At 0330 h, a bolus of 200 yCi 2-[3H] glycerol was injected intravenously to label endogenously synthesized VLDL TGG.
4 h later, at 0730 h, the '3'I-VLDL previously isolated from the subject was injected intravenously and began a 3-h baseline sampling period.
(a) Insulin infusion study Calculation of changes in VLDL-triglyceride and VLDL-apo B production rates
The semiquantitative method used in this study has been described in detail previously (21) . We have shown that, under steady-state conditions, the decline in VLDL [3H]TGG sp act and '3'I-VLDL apo B sp act for the length of time examined in the present study is monoexponential and that fasting VLDL is a valid tracer for hyperinsulinemic VLDL.
The 4-h time lapse between the administration of [3H] glycerol and the beginning of the baseline sampling period allowed the VLDL [3H] TGG sp act to peak and then begin declining, such that the rate of decline of sp act in the VLDL fraction could be examined. Apo B sp act, on the other hand, declines almost immediately after administration and the slope of the decline is predictable for at least 9 h. Under steady-state conditions, the slope of the sp act versus time curve reflects the input of unlabeled (i.e., newly made) VLDL triglyceride and apo B into the circulating VLDL triglyceride and apo B pools, respectively, as a fraction of that pool. Although changes in removal, which are likely to occur during the initial 1-3 h of hyperinsulinemia (when VLDL is not in steady state), may also affect the slope of the curve, the slope is only examined once a new steady state is reached, and therefore a change in the slope reflects a change in production. We were therefore able to determine the change in endogenous VLDL triglyceride and apo B production relative to baseline by calculating the change in slope occurring with an acute manipulation such as the infusion of insulin or Intralipid plus heparin. The slopes for VLDL [3H]TGG sp act and '3'I-VLDL apo B sp act versus time were calculated during the 3-h baseline period and again after the manipulation, when a new steady state was reached (generally within 1-3 h). The slope after the manipulation was corrected for the actual change in VLDL triglyceride or VLDL apo B pool size, to allow for the change in slope that would result from a change in pool size alone. Since the volume of distribution Insulin Regulation of VLDL Production If endogenous VLDL triglyceride or apo B production increases, the second slope (adjusted for change in pool size) will be steeper than the baseline slope. If production decreases, the slope will flatten. Since we studied a relatively homogeneous group of subjects, all of whom had normal fasting triglyceride levels, the interindividual variation in basal VLDL production rate would be expected to be rather small. Therefore, expression of the results as percent change in VLDL production from baseline permits a valid comparison between the individuals participating in the three studies.
Laboratory methods
Glucose was analyzed enzymatically using a Glucose Analyzer II (Beckman Instruments Corp., Fullerton, CA). Insulin was measured by radioimmunoassay using a double antibody separation method (kit supplied by Pharmacia Diagnostic, Uppsala, Sweden) (32) (intraassay coefficient of variation [cv] = 6.7%, interassay cv = 4.6%). Cholesterol was measured using the CHOD-PAP enzymatic colorimetric kit (Boehringer Mannheim GambH Diagnostica, Montreal, Canada) (intraassay cv = 1.4%, interassay cv = 2.9%). Triglycerides were measured as esterified glycerol using the enzymatic calorimetric kit (Boehringer Mannheim GmbH Diagnostica). Free glycerol was eliminated from the sample in a preliminary reaction followed by enzymatic hydrolysis of triglyceride with subsequent determination of the liberated glycerol by 160 Lewis, Uffelman, Szeto, Weller, and Steiner 
Results
Glucose and insulin concentrations (Fig. 1) and dextrose infusion rates. In both euglycemic hyperinsulinemic clamp studies, with or without the addition of heparin and Intralipid, plasma glucose levels were maintained in the euglycemic range with a coefficient of variation of 8.8% and 8.7%, respectively. Plasma insulin levels were elevated to a similar extent in both studies (409.5±13.3 and 381.5±16.8 pmol/liter, respectively, mean±SEM). In the study in which heparin and Intralipid were infused without exogenous insulin, glucose and insulin remained at basal concentrations.
20% dextrose infusion rates, calculated for the final 30 min of the euglycemic hyperinsulinemic clamp, were similar in the two studies in which insulin was infused (237±15 ml/h with insulin alone vs. 229±21 ml/h with insulin plus Intralipid and heparin, P = NS). Since hepatic glucose production has been shown to be > 95% suppressed in normal insulin-sensitive individuals at the levels of peripheral hyperinsulinemia achieved in Plasma apo B declined in both the insulin infusion study (60.8+8.4 to 52.7±7.2 mg/dl, P = 0.009) and in the insulin/ heparin/Intralipid study (64.3±5.2 to 59.5+6.4 mg/dl, P = 0.03). When heparin and Intralipid were infused without insulin, apo B levels remained constant (60.5±4.8 to 60.1±4.1 mg/dl, P = NS).
VLDL composition (Fig. 1) . VLDL triglyceride concentration decreased with insulin alone (0.91±0.23 to 0.57±0.19 mmol/liter, P = 0.004), remained unchanged with insulin/heparin/Intralipid (0.81±0.14 to 0.74+0.17 mmol/liter, P = NS) and increased with heparin/Intralipid (0.58±0.08 to 0.86±0.13 mmol/liter, P = 0.007). Differences between all three studies between 300 and 480 min were significant at P = 0.01.
VLDL apo B decreased with insulin alone (12.5±2.9 to 10.6±2.8 mg/dl, P = 0.03), did not change with insulin/heparin/Intralipid (14.6±2.6 to 14.9±3.4 mg/dl, P = NS) and increased with heparin/Intralipid (9.6±1.3 to 14.5±1.7 mg/dl, P = 0.002).
VLDL triglyceride and apo B levels increased or decreased in individual subjects, reaching a new steady state by 30 min to 3 h after the onset of hyperinsulinemia or the Intralipid infusion. Any further change was < 5% in the majority and < 10% in all subjects.
VLDL triglyceride and apo B production rates (Figs. 2 and  3, Tables I, II, and III) . With the exogenous insulin infusion alone, VLDL triglyceride production decreased by 66.7±4.2% (P = 0.0001) and VLDL apo B production decreased by 51.7±10.6% (P = 0.003). When plasma FFA levels were raised twofold by infusing heparin and Intralipid with insulin, VLDL triglyceride production decreased by 31.8±9.5% (P = 0.03) and apo B production did not decrease significantly (-6.3±13.6%, P = NS). The decreases in production of both VLDL triglyceride and VLDL apo B were greater in the insulin infusion study than in the insulin/heparin/Intralipid study (paired t test, P = 0.006 and P = 0.04, respectively). The triglyceride data from one subject were not included in the analysis due to the variability of the data, and the radioactivity of the apo B was not included from another as it was < 1.5 times background.
When heparin and Intralipid were infused without insulin, VLDL triglyceride production increased by 180.1±45.7% (P = 0.008) and apo B production increased by 94.2±28.7% (P = 0.05). The VLDL triglyceride data from one individual and apo B data from a second individual were omitted from the analysis for reasons cited above.
There were no significant correlations between area under the FFA curve (after 180 min) and the magnitude of change in VLDL production.
Discussion
In the present study we have tested the hypothesis that insulin has an acute suppressive effect on VLDL production in humans independent of the effect of FFA. We have confirmed our previous findings that insulin acutely suppresses VLDL triglyceride and VLDL apo B production in lean healthy individuals (21, 22 ). We have also demonstrated, for the first time, that an acute elevation of plasma FFA stimulates VLDL production in humans. When both plasma FFA and insulin levels were raised simultaneously, there remained a significant reduction in VLDL triglyceride production (although VLDL apo B production did not increase or decrease significantly). The magnitude of this reduction was less than with insulin alone. We have therefore shown that insulin has an acute suppressive effect on VLDL triglyceride production in young healthy males, independent of the effect of a reduction in plasma FFA. However, at least part of the acute suppressive effect of insulin on VLDL production can be explained by the decrease in plasma FFA that occurs with acute hyperinsulinemia.
Byrne et al. (13) reported similar effects in HepG2 cells. Supplementing the cell culture medium with oleic acid diminished the insulin-induced inhibition of triglyceride secretion from 18.2 to 7.8%. Others (11, 12, 15) have also studied the interaction of oleate and insulin on secretion of lipoproteins in HepG2 cells. Oleate resulted in a marked stimulation of VLDL secretion whereas insulin caused a significant decrease. Insulin limited the oleate-induced stimulation of VLDL secretion ( 11). However, in the latter experiment ( 11 ) the combination of insulin and oleate in the medium still resulted in a net increase in VLDL secretion above basal. The interpretation of these studies depends on the basal VLDL secretion rate.
In the present studies, when the hyperinsulinemia-induced decline in FFA was prevented, the reduction in VLDL triglyceride production was still reduced but this was less than during hyperinsulinemia alone. Under the same conditions insulin no longer inhibited VLDL apo B production. However, one must caution the reader against overinterpreting the changes in apo B as there was considerable variability in the apo B production data in the insulin-heparin-Intralipid study. Our data would suggest that the acute inhibitory effect of insulin on VLDL production in vivo is due in part to the suppression of plasma FFA. However, at least with respect to VLDL triglyceride production, insulin appears to have some additional effect, perhaps acting directly on the hepatocyte to inhibit VLDL production. FFA are rapidly taken up by hepatocytes and esterified before entry into the cytoplasmic pool of triglyceride. Gibbons et al. (27) have suggested that the size of this cytoplasmic triglyceride pool, rather than the availability of extracellular oleic acid, correlated with VLDL secretion. In rat hepatocytes, 70% of VLDL triglyceride secreted is derived by the lipolysis of cytoplasmic triglycerides with re-esterification near the site of VLDL assembly with apo B (38) . This proportion is not affected by insulin and intracellular lipolysis of stored triglyceride does not appear to be rate-limiting for VLDL assembly (38) .
The assembly and secretion of VLDL requires apo B synthesis and a metabolically accessible pool of VLDL lipid components, including triglycerides and cholesteryl esters (39) . A number of investigators have shown that insulin leads to en- Statistics are by paired t test comparing adjusted slope during hyperinsulinemia to the baseline slope. Note that apo B sp act data for subject 12 and TG sp act data for subject 14 were not included because sp act was either not > 1.5 x background activity or poor regressions for decay curves. secretion is increased from perfused liver of fasted rats (49) . One should exercise some caution in extrapolating the results of the present study to explain the physiological role of postprandial hyperinsulinemia in controlling VLDL production.
Apo B and triglyceride each reflect different components of VLDL. The parallel changes in the relative production rates for each strengthens the conclusions that can be drawn from these studies.
In conclusion we have shown that insulin inhibits VLDL production acutely in healthy young males, both via its ability to suppress FFA mobilization from peripheral tissues as well as by some other mechanism, perhaps a direct hepatic effect. As suggested by Sparks and Sparks (39) this suppressive effect of insulin may play an important role in limiting the postprandial competition between hepatic and intestinal triglyceride-rich lipoprotein particles for clearance during feeding while at the same time promoting hepatic triglyceride storage, thus smoothing out the transition from fed-to-fasting states.
